There is a critical need for predictive biomarkers in clinical research. Patients and payers demand greater efficacy and safety windows. Due to scarce research funding, drug developers are forced to select projects they are confident in early on in their development for investment and further investigation in expensive phase III studies. While the need is clear, the most frequently used methods of quantification within serum or plasma samples are more than two decades old. These methods quantify total proteins and overlook new developments and understanding of proteins as complex players that have multiple functions. Separately quantifying each part of the protein provides more information, by assessing the formation of the protein, the degradation of the proteins and potential signaling domains, rather than a crude measure of the total protein. In fact, many chronic diseases like osteoporosis, osteoarthritis, fibrosis of the liver, lung, kidney, skin, intestine, and heart result from an imbalance between the formation and degradation of tissue.
Please don't hesitate to contact us if you have any questions or other inquiries.